The main aim of this project was to explore and strengthen the business plan of a new spin-off, Cenya Imaging BV. Cenya means "to see" in Tolkien's Elvish, and Cenya deals with imaging agents. New imaging agents are extremely challening to bring to clinical use, and the Cenya agents are a new type of imaging agent- combining multifunctionality with multimodality. Our main focus has been cell tracking, where we can quantitatively image cells to optimise therapies, for example therapeutic immune cells in oncology, or stem cells in regenerative medicine. This would allow a noninvasive, and longitudinal biomaker to both help optimise the therapy and gain a fundamental understanding of what is going on at the cellular level in vivo.
Through this project, we were able to build several collaborations, including with large pharma, and strengthen our company. The pandemic complicated our publicity and outreach activities, but overall, we made progress and hit our Deliverables in the project.
Cenya is now a growing company, that is able to collaborate and produce imaging agents for various applications. We are working hard to bring noninvasive imaging to the optimisation of advanced therapeutics to improve patient outcome in the near future.
